Drug Profile
Calcium acetate - PUMC Pharmaceutical
Alternative Names: PhosminLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator PUMC Pharmaceutical Company
- Class Acetates; Calcium supplements; Electrolytes; Small molecules
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperphosphataemia
Most Recent Events
- 28 Aug 2023 Discontinued - Preclinical for Hyperphosphataemia in China (PUMC Pharmaceutical pipeline)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Hyperphosphataemia in China (Tablet)
- 06 Jan 2016 Preclinical trials in Hyperphosphataemia in China (unspecified route) before January 2016